title: Outcomes in meningitis/ventriculitis treated with intravenous or intraventricular plus intravenous colistin.
abstract: BACKGROUND
  The aim of this work is to evaluate the outcome of patients treated with intrathecal colistin for meningitis/ventriculitis.
  
  
  METHODS
  This retrospective case series study included patients presenting with nosocomial meningitis/ventriculitis following neurosurgical interventions and having intravenous (IVC group) or intravenous and intrathecal/intraventricular colistin (ITC group) treatment between 2006 and 2014.
  
  
  RESULTS
  Thirty-four patients presented nosocomial meningitis/ventriculitis; 11 (32.5 %) were included in the IVC group and 23 (67.6 %) in the ITC group. The most frequent isolated bacteria were Acinetobacter baumannii. The mean dose was 170,000 (±400) IU and the duration of intraventricular treatment was 16.0 (±8.3) days. The duration of intravenous treatment was 16.0 (±8.3) days in the ITC group and 15.3 ± 7.6 days in IVC group. Hospital mortality was significantly lower in the ITC group compared with the IVC group (13 vs. 72.7 %, p = 0.001).
  
  
  CONCLUSIONS
  The combination of intravenous plus intraventricular (IV-IVT) colistin therapy may improve outcomes in patients attending with meningitis/ventriculitis due to multi-drug resistance infections.
authors.affiliation: Department of Neurosurgery, University Hospital of Thessaly, University Hospital of Larissa, Biopolis, 41110, Larissa, Thessaly, Greece. gfotakop@yahoo.gr.|, Vounargo, Pyrgou, Ilias, 27100, Greece. gfotakop@yahoo.gr.
authors.forename: George
authors.initials: G
authors.lastname: Fotakopoulos
authors.affiliation: Department of Head of Critical Care, University of Thessaly, University Hospital of Larissa, Biopolis, 41110, Larissa, Thessaly, Greece.
authors.forename: Demosthenes
authors.initials: D
authors.lastname: Makris
authors.affiliation: Department of Head of Critical Care, University of Thessaly, University Hospital of Larissa, Biopolis, 41110, Larissa, Thessaly, Greece.
authors.forename: Maria
authors.initials: M
authors.lastname: Chatzi
authors.affiliation: Department of Head of Critical Care, University of Thessaly, University Hospital of Larissa, Biopolis, 41110, Larissa, Thessaly, Greece.
authors.forename: Eleni
authors.initials: E
authors.lastname: Tsimitrea
authors.affiliation: Department of Head of Critical Care, University of Thessaly, University Hospital of Larissa, Biopolis, 41110, Larissa, Thessaly, Greece.
authors.forename: Epaminondas
authors.initials: E
authors.lastname: Zakynthinos
authors.affiliation: Department of Neurosurgery, University Hospital of Thessaly, University Hospital of Larissa, Biopolis, 41110, Larissa, Thessaly, Greece.
authors.forename: Kostas
authors.initials: K
authors.lastname: Fountas
mesh_terms: D000151:Acinetobacter Infections / Q000188:drug therapy*; D061605:Administration, Intravenous; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D058565:Cerebral Ventriculitis / Q000188:drug therapy*; D003091:Colistin / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007276:Injections, Intraventricular; D008297:Male; D016920:Meningitis, Bacterial / Q000188:drug therapy*; D008875:Middle Aged
chemical_list: D000900:Anti-Bacterial Agents; D003091:Colistin
keywords: CNS infections; Intrathecal/intraventricular colistin treatment; Nosocomial meningitis/ventriculitis